Last reviewed · How we verify

Intravenous Sedatives

University of Florida · FDA-approved active Small molecule

Intravenous sedatives depress the central nervous system to produce sedation, anxiolysis, and unconsciousness for medical procedures and critical care.

Intravenous sedatives depress the central nervous system to produce sedation, anxiolysis, and unconsciousness for medical procedures and critical care. Used for Induction and maintenance of general anesthesia, Procedural sedation and anxiolysis, Intensive care unit sedation.

At a glance

Generic nameIntravenous Sedatives
Also known asPropofol or Dexmedetomidine
SponsorUniversity of Florida
Drug classCentral nervous system depressant / Sedative-hypnotic
TargetGABA-A receptor (primary for most IV sedatives)
ModalitySmall molecule
Therapeutic areaAnesthesia / Critical Care / Procedural Sedation
PhaseFDA-approved

Mechanism of action

IV sedatives work by enhancing inhibitory neurotransmission in the brain, primarily through GABA-A receptor agonism (for benzodiazepines and propofol) or other CNS depressant pathways. This results in reduced consciousness, muscle relaxation, and amnesia, making them essential for anesthesia induction, procedural sedation, and ICU sedation management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: